|
ZNF530 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62481139653892E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.22044604925031E-15 |
| Normal-vs-Stage2 |
2.73159999997219E-06 |
| Normal-vs-Stage3 |
6.82349732272769E-11 |
| Normal-vs-Stage4 |
5.9089955151137E-11 |
| Stage1-vs-Stage2 |
2.657200E-01 |
| Stage1-vs-Stage3 |
7.444000E-01 |
| Stage1-vs-Stage4 |
6.818300E-02 |
| Stage2-vs-Stage3 |
2.682200E-01 |
| Stage2-vs-Stage4 |
3.850300E-02 |
| Stage3-vs-Stage4 |
1.975820E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.31006316905768E-14 |
| Normal-vs-AfricanAmerican |
4.05850000000374E-05 |
| Normal-vs-Asian |
1.58606999999256E-05 |
| Caucasian-vs-AfricanAmerican |
6.606200E-01 |
| Caucasian-vs-Asian |
8.789800E-02 |
| AfricanAmerican-vs-Asian |
4.540000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.56769996983996E-09 |
| Normal-vs-Female |
1.62481139653892E-12 |
| Male-vs-Female |
8.480000E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.28650431921551E-11 |
| Normal-vs-Age(41-60Yrs) |
7.59203810929421E-12 |
| Normal-vs-Age(61-80Yrs) |
7.88490384096008E-11 |
| Normal-vs-Age(81-100Yrs) |
1.006040E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.598800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.543800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.915600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.570000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.428600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.846400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.188100E-02 |
| Classical-VS-Follicular |
2.871000E-01 |
| Classical-VS-Other |
2.634400E-01 |
| Classical-VS-Normal |
1.73883130116792E-12 |
| Tall-VS-Follicular |
3.126000E-01 |
| Tall-VS-Other |
9.023400E-01 |
| Tall-VS-Normal |
4.87660001269319E-09 |
| Follicular-VS-Other |
5.222400E-01 |
| Follicular-VS-Normal |
8.20229995035504E-10 |
| Other-VS-Normal |
6.626900E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.08240108384916E-12 |
| Normal-vs-N1 |
9.27019572216636E-11 |
| N0-vs-N1 |
3.144100E-02 |
|
|
